Thromboxane A2 and Osteoarthritis

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40+
SponsorCentre Hospitalier Universitaire de Nice

About this trial

TXA2 inhibits the expression of the primary marker of thermogenesis (UCP1) while prostacyclin (PGI2), another metabolite derived from arachidonic acid, enhances its expression. Given the close relationship between the adipocyte and the chondrocyte, the study team hypothesises that thromboxane A2 controls chondrocyte formation and function and thus cartilage homeostasis. The study objectives are: i) to analyse the role of TXA2 on chondrocyte differentiation in vitro, ii) to determine the association between circulating and tissue TXA2 levels in a rat model of osteoarthritis, and iii) to correlate circulating and synovial fluid levels of TXA2 with the development of osteoarthritis in a small human cohort. The proposed research aims to better understand the mechanisms underlying the role of lipid metabolites in chondrocyte formation and function, paving the way for the development of nutritional and pharmacological therapies to combat OA and associated metabolic disorders.

Eligibility criteria

Qualifiers

presence of knee osteoarthritis with effusion, , no inflammatory disease

Disqualifiers

anticoagulant treatment

inflammatory disease

Trial design

Treatments tested in this trial

  • biological samples

Treatment groups

20 Participants
are divided into 1 treatment group

Sponsors and collaborators

Centre Hospitalier Universitaire de Nice

Lead sponsor

French Society of Rheumatology

Collaborator